论文部分内容阅读
目的探讨顺铂联合培美曲塞或多西他赛治疗晚期非小细胞肺癌(NSCLC)的临床疗效及其安全性。方法选取武警四川省总队医院肿瘤科2015年5月—2016年11月收治的晚期NSCLC患者58例,按照入院顺序分为PP组(n=30)和DP组(n=28)。患者入院后均给予常规基础治疗,PP组患者给予顺铂+培美曲塞治疗方案,DP组患者给予顺铂+多西他赛治疗方案,两组患者均持续治疗2~6个周期。比较两组患者的近期疗效、毒副作用及Karnofsky评分法(KPS)评分。结果两组患者肿瘤控制率比较,差异无统计学意义(P>0.05);PP组患者治疗有效率高于DP组(P<0.05)。两组患者白细胞计数减少、消化道反应发生率及其他毒副作用发生率比较,差异无统计学意义(P>0.05)。治疗前,两组患者KPS评分比较,差异无统计学意义(P>0.05);治疗后,PP组患者KPS评分高于DP组(P<0.05)。结论采用培美曲塞联合顺铂治疗晚期NSCLC的临床疗效优于多西他赛,其可有效提高患者的生活质量,且并不会增加药物毒副作用。
Objective To investigate the clinical efficacy and safety of cisplatin plus pemetrexed or docetaxel in the treatment of advanced non-small cell lung cancer (NSCLC). Methods Fifty-eight patients with advanced NSCLC who were admitted to Department of Oncology, Sichuan Provincial Corps Hospital from May 2015 to November 2016 were divided into PP group (n = 30) and DP group (n = 28) according to admission order. All patients were given routine basic treatment after admission. Patients in PP group were treated with cisplatin and pemetrexed. Patients in DP group were treated with cisplatin and docetaxel. Patients in both groups were treated continuously for 2 to 6 cycles. The curative effect, side effects and Karnofsky score (KPS) were compared between the two groups. Results There was no significant difference in tumor control rate between the two groups (P> 0.05). The treatment efficiency of PP group was higher than that of DP group (P <0.05). The two groups of patients with decreased white blood cell count, the incidence of gastrointestinal reactions and other toxic and side effects of the incidence, the difference was not statistically significant (P> 0.05). Before treatment, there was no significant difference in KPS score between the two groups (P> 0.05). After treatment, KPS score of PP group was higher than that of DP group (P <0.05). Conclusions Pemetrexed plus cisplatin is superior to Docetaxel in the treatment of advanced NSCLC, which can effectively improve the quality of life of patients without increasing the side effects of drugs.